看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 1.1x - 1.2x | 1.1x |
| Selected Fwd Ps Multiple | 1.0x - 1.1x | 1.1x |
| Fair Value | $9.24 - $10.22 | $9.73 |
| Upside | 16.3% - 28.5% | 22.4% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| SI-BONE, Inc. | - | NasdaqGM:SIBN |
| Globus Medical, Inc. | - | NYSE:GMED |
| Enovis Corporation | - | NYSE:ENOV |
| Alphatec Holdings, Inc. | - | NasdaqGS:ATEC |
| Boston Scientific Corporation | - | NYSE:BSX |
| Bioventus Inc. | - | NasdaqGS:BVS |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| SIBN | GMED | ENOV | ATEC | BSX | BVS | |||
| NasdaqGM:SIBN | NYSE:GMED | NYSE:ENOV | NasdaqGS:ATEC | NYSE:BSX | NasdaqGS:BVS | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 20.0% | 26.3% | -8.7% | 40.1% | 9.3% | 11.0% | ||
| 3Y CAGR | 22.9% | 38.0% | 13.9% | 36.0% | 12.1% | 10.0% | ||
| Latest Twelve Months | 20.4% | 60.6% | 23.5% | 26.8% | 17.6% | 11.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -49.4% | 13.1% | -2.6% | -46.8% | 12.3% | -14.2% | ||
| Prior Fiscal Year | -31.2% | 7.8% | -3.2% | -38.7% | 11.0% | -18.9% | ||
| Latest Fiscal Year | -18.5% | 4.1% | -39.3% | -26.5% | 11.1% | -5.9% | ||
| Latest Twelve Months | -18.5% | 4.1% | -39.3% | -26.5% | 11.1% | -5.9% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -14.3x | 13.0x | 9.8x | -43.6x | 36.1x | 14.6x | ||
| Price / LTM Sales | 3.3x | 3.7x | 0.9x | 2.4x | 8.5x | 0.9x | ||
| LTM P/E Ratio | -17.9x | 91.7x | -2.4x | -8.9x | 77.2x | -15.1x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.9x | 3.3x | 8.5x | |||||
| Historical LTM P/S Ratio | 0.0x | 0.7x | 2.2x | |||||
| Selected Price / Sales Multiple | 1.1x | 1.1x | 1.2x | |||||
| (x) LTM Sales | 573 | 573 | 573 | |||||
| (=) Equity Value | 620 | 652 | 685 | |||||
| (/) Shares Outstanding | 66.2 | 66.2 | 66.2 | |||||
| Implied Value Range | 9.36 | 9.86 | 10.35 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 9.36 | 9.86 | 10.35 | 7.95 | ||||
| Upside / (Downside) | 17.8% | 24.0% | 30.2% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | SIBN | GMED | ENOV | ATEC | BSX | BVS | |
| Value of Common Equity | 591 | 10,217 | 1,949 | 1,449 | 143,130 | 526 | |
| (/) Shares Outstanding | 42.5 | 137.5 | 57.0 | 144.1 | 1,479.1 | 66.2 | |
| Implied Stock Price | 13.92 | 74.28 | 34.22 | 10.05 | 96.77 | 7.95 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 13.92 | 74.28 | 34.22 | 10.05 | 96.77 | 7.95 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |